Virbac extends IBM partnership, shares backed by steady analyst consensus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:16.

Virbac (FR0000031577) is expanding its collaboration with IBM in digital solutions for animal health operations. The partnership extension, highlighted in mid-June news flow, adds a technology layer to the French group’s veterinary focus, with the stock referenced on Euronext Paris and tracked by MarketScreener analyst data.MarketScreener overview on Virbac and recent IBM partnership note

What the IBM partnership adds

IBM’s extended partnership with Virbac was flagged on 19 June 2026 in secondary coverage, indicating a continued push into data and digital tools for animal health professionals.MarketScreener summary mentioning the IBM collaboration The cooperation supports Virbac’s operational backbone, including logistics, information systems and potentially decision-support tools for veterinarians.

While detailed financial terms were not publicly broken out, the extension underscores Virbac’s strategic use of global IT providers such as IBM to underpin its mid-size pharmaceutical platform. The animal health peer group includes players like Zoetis and Elanco in the US, making digital capability an increasingly relevant competitive factor.

Analyst views and stock metrics

Consensus data compiled by MarketScreener show a middle price target for Virbac shares at around 412.88 euros, compared with a last closing price near 338 euros on the French market as of 22 June 2026.MarketScreener Virbac quote and analyst target data This points to a documented upside in analyst models, though the stance remains cautious rather than aggressive.

The same data set indicates that analyst coverage of Virbac is relatively limited compared with large-cap healthcare names, but those following the stock factor in stable demand for veterinary products. The French listing on Euronext Paris anchors Virbac in the European mid-cap healthcare space, adjacent in sector terms to companies such as Vétoquinol.

The product behind the stock

Virbac generates its revenue with a global portfolio of veterinary medicines and health products for companion animals and livestock. A representative line is its parasiticide and dermatology treatments for dogs and cats, used by veterinarians to manage fleas, ticks and skin conditions in small animals.

Where the shares trade today

The Virbac shares (FR0000031577) traded on Euronext Paris at around 338.00 euros at the close on 2026-06-22, based on MarketScreener price data in euros.MarketScreener Virbac closing price overview

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance.